RXST · RxSight Inc
United States · RS rating 21 · As of 2026-11-03
| Price | 4.59 USD |
|---|---|
| 1-day change | -4.4% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 48 / 23 / 23 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 10 / 21 |
| Industry group (rank) | Medical-Products (106) |
| EPS growth Q/Q | +8.3% |
| Sales growth Q/Q | +7.5% |
| Distance from 52-week high | +64.9% |
| Market cap (USD) | $297.1M |